L-ornithine L-aspartate in Overt Hepatic Encephalopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Cirrhosis of LiverHepatic Encephalopathy
Interventions
DRUG

L-ornithine L-aspartate

L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days

DRUG

Placebo

Placebo (sterile water, 60 ml) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days

Trial Locations (2)

110002

G.B. Pant Hospital, New Delhi

141001

Department of Gastroenterology, D.M.C. and Hospital, Ludhiana

All Listed Sponsors
lead

Dayanand Medical College and Hospital

OTHER

NCT01722578 - L-ornithine L-aspartate in Overt Hepatic Encephalopathy | Biotech Hunter | Biotech Hunter